Barinthus Biotherapeutics plc 2AB.F Stock
Barinthus Biotherapeutics plc Price Chart
Barinthus Biotherapeutics plc 2AB.F Financial and Trading Overview
| Barinthus Biotherapeutics plc stock price | 1.95 EUR |
| Previous Close | 2.1 EUR |
| Open | 2.18 EUR |
| Bid | 2.18 EUR x N/A |
| Ask | 2.38 EUR x N/A |
| Day's Range | 2.18 - 2.18 EUR |
| 52 Week Range | 1.88 - 5.75 EUR |
| Volume | 100 EUR |
| Avg. Volume | 1 EUR |
| Market Cap | 88.12M EUR |
| Beta (5Y Monthly) | 0.167278 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.77 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.5 EUR |
2AB.F Valuation Measures
| Enterprise Value | -99829344 EUR |
| Trailing P/E | N/A |
| Forward P/E | -2.2947369 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.9223697 |
| Price/Book (mrq) | 0.35212407 |
| Enterprise Value/Revenue | -3.311 |
| Enterprise Value/EBITDA | 4.257 |
Trading Information
Barinthus Biotherapeutics plc Stock Price History
| Beta (5Y Monthly) | 0.167278 |
| 52-Week Change | -41.71% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.75 EUR |
| 52 Week Low | 1.88 EUR |
| 50-Day Moving Average | 2.1 EUR |
| 200-Day Moving Average | 2.52 EUR |
2AB.F Share Statistics
| Avg. Volume (3 month) | 1 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 38.37M |
| Float | 26.89M |
| Short Ratio | N/A |
| % Held by Insiders | 26.37% |
| % Held by Institutions | 26.98% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -51.18% |
| Operating Margin (ttm) | -82.34% |
| Gross Margin | -37.50% |
| EBITDA Margin | -77.77% |
Management Effectiveness
| Return on Assets (ttm) | -5.66% |
| Return on Equity (ttm) | -6.35% |
Income Statement
| Revenue (ttm) | 30.15M EUR |
| Revenue Per Share (ttm) | 0.81 EUR |
| Quarterly Revenue Growth (yoy) | -96.89% |
| Gross Profit (ttm) | N/A |
| EBITDA | -23452000 EUR |
| Net Income Avi to Common (ttm) | -15434000 EUR |
| Diluted EPS (ttm) | -0.4 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 191.33M EUR |
| Total Cash Per Share (mrq) | 4.99 EUR |
| Total Debt (mrq) | 10.65M EUR |
| Total Debt/Equity (mrq) | 4.56 EUR |
| Current Ratio (mrq) | 16.739 |
| Book Value Per Share (mrq) | 6.191 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -11026000 EUR |
| Levered Free Cash Flow (ttm) | 5.66M EUR |
Profile of Barinthus Biotherapeutics plc
| Country | Germany |
| State | N/A |
| City | Harwell |
| Address | Zeus Building |
| ZIP | OX11 0DF |
| Phone | 44 1865 818 808 |
| Website | https://www.vaccitech.co.uk |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 33 |
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
Q&A For Barinthus Biotherapeutics plc Stock
What is a current 2AB.F stock price?
Barinthus Biotherapeutics plc 2AB.F stock price today per share is 1.95 EUR.
How to purchase Barinthus Biotherapeutics plc stock?
You can buy 2AB.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Barinthus Biotherapeutics plc?
The stock symbol or ticker of Barinthus Biotherapeutics plc is 2AB.F.
Which industry does the Barinthus Biotherapeutics plc company belong to?
The Barinthus Biotherapeutics plc industry is Biotechnology.
How many shares does Barinthus Biotherapeutics plc have in circulation?
The max supply of Barinthus Biotherapeutics plc shares is 39.43M.
What is Barinthus Biotherapeutics plc Price to Earnings Ratio (PE Ratio)?
Barinthus Biotherapeutics plc PE Ratio is now.
What was Barinthus Biotherapeutics plc earnings per share over the trailing 12 months (TTM)?
Barinthus Biotherapeutics plc EPS is -1.77 EUR over the trailing 12 months.
Which sector does the Barinthus Biotherapeutics plc company belong to?
The Barinthus Biotherapeutics plc sector is Healthcare.